John LaRosa – Page 4 – Diet Business Watch

Medifast Reports First Quarter Results – Slide Continues

April 28, 2025 According to CEO Dan Chard: “This year, we are focused on revitalizing our coach and customer base by supporting them with enhanced tools, data, and new products. Our business focus remains on reestablishing sustainable long-term growth while improving profitability.” First quarter 2025 revenue decreased 33.8% to $115.7 million from $174.7 million for the […]

Medifast Reports First Quarter Results – Slide Continues Read More »

2022 Census Data Published: Commercial Weight Loss Industry Statistics

News / John LaRosa

April 24, 2025 The U.S. Census of Service Industries is performed every 5 years, with the last government survey performed in 2022. Commercial weight loss companies (“diet & reducing centers”) are classified under NAICS code 812191 (other personal services). Establishment and firms data for this industry have just been released (see census.gov). This information is

2022 Census Data Published: Commercial Weight Loss Industry Statistics Read More »

Novo Nordisk Submits Weight Loss Pill for FDA Approval

News / John LaRosa

April 24, 2025 Novo Nordisk asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this year, a spokesperson confirmed. The company first reported in 2023 that the drug, an oral form of semaglutide, succeeded in a Phase 3 trial, helping people on the highest

Novo Nordisk Submits Weight Loss Pill for FDA Approval Read More »

$5 Billion U.S. Meal Replacements Market Survives GLP-1s Competition

News / John LaRosa

April 22, 2025 Marketdata LLC has just released a new market study: “The U.S. Meal Replacements Market: Retail & MLM Channels”, April 2025. This 77-page report analyses the meal replacements and retail appetite suppressants market in the U.S. The $5.1 billion U.S. meal replacements market has held up fairly well the past few years, despite

$5 Billion U.S. Meal Replacements Market Survives GLP-1s Competition Read More »

Eli Lilly’s New Weight Loss Pill Shows Promise

News / John LaRosa

April 17, 2025 New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6%

Eli Lilly’s New Weight Loss Pill Shows Promise Read More »

Gyms Start Selling GLP-1 Drugs? The Bandwagon Gets More Crowded

News / John LaRosa

April 12, 2025 We noticed a post on Instagram today that pitches a company that will set up a medical weight loss program, using GLP-1 drugs for gyms. We shouldn’t be surprised. Everyone else has entered the GLP-1 gold rush, including med spas, so why not gyms as well? The company offering this “opportunity” is

Gyms Start Selling GLP-1 Drugs? The Bandwagon Gets More Crowded Read More »

Weight Watchers Prepares for Possible Bankruptcy Filing

News / John LaRosa

April 9, 2025 (Reuters) – WW International may be preparing to file for bankruptcy in the coming months as part of a plan to hand control of the business to its creditors, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Shares of the company tumbled nearly 59% to 18 cents

Weight Watchers Prepares for Possible Bankruptcy Filing Read More »

Weight Watchers Investor Seeks Board Seats

News / John LaRosa

April 3, 2025 Premca Capital, an investment fund, has nominated three directors for election to WW International’s board, according to the people familiar with the matter. WW has a market capitalization of about $40 million, following a sharp decline in its shares in recent years. Its stock is down nearly 70% in the past year, due

Weight Watchers Investor Seeks Board Seats Read More »

Robard Begins Selling Diet Foods Direct to Consumers

News / John LaRosa

April 2, 2025 Robard, the medical weight loss company, has begun selling its shakes, puddings, soups and beverages direct to the public via a new website. These products are part of its New Direction program. This is a departure from its long-standing policy where you had to sign up for the program to get access

Robard Begins Selling Diet Foods Direct to Consumers Read More »

A Recession Is NOT The Time To Cut Marketing

News / John LaRosa

March 31, 2025 Many economists and analysts are saying that a recession is coming sometime this year. That said, many weight loss companies and their top managers will say they’ll have to cut expenses, especially marketing. That’s the knee-jerk reaction, but it’s dead wrong. When consumers cut back on spending, they will revert to trusted

A Recession Is NOT The Time To Cut Marketing Read More »

(813) 971-8080

Author name: John LaRosa

Medifast Reports First Quarter Results – Slide Continues

2022 Census Data Published: Commercial Weight Loss Industry Statistics

Novo Nordisk Submits Weight Loss Pill for FDA Approval

$5 Billion U.S. Meal Replacements Market Survives GLP-1s Competition

Eli Lilly’s New Weight Loss Pill Shows Promise

Gyms Start Selling GLP-1 Drugs? The Bandwagon Gets More Crowded

Weight Watchers Prepares for Possible Bankruptcy Filing

Weight Watchers Investor Seeks Board Seats

Robard Begins Selling Diet Foods Direct to Consumers

A Recession Is NOT The Time To Cut Marketing